ai3Bio
ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease.
$48MSeries A
LeadUE
UPMC Enterprises
Activity from announced rounds
Activity in this selectionHealthtech
UPMC Enterprises is the organization identified in its own RAAPID, BrainCheck and ai3Bio materials.
Recorded funding activity
RAAPID supplies healthcare risk-adjustment software. Ai3Bio develops immune-cell-targeted medicines. The pending ai3Bio relation stays in draft, and the organization remains separate from UPMC and the University of Pittsburgh.
- Rounds participated in
- 4
- Confirmed lead rounds
- 1 3 roles undisclosed
- New companies
- 3 First participation on record · 1 follow-on
- Funding in participating rounds
- $61M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionRAAPID
Provides AI-powered risk adjustment solutions for healthcare
UndisclosedStrategic
Role not disclosedRAAPID
Provides AI-powered risk adjustment solutions for healthcare
UndisclosedSeries A+
Role not disclosedBrainCheck
Provides digital cognitive assessment and care for healthcare organizations
$13MSeries A
Role not disclosed